Takeda (TAK) and Vela Transport announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using Vela’s sailing cargo trimaran. Vela designed and will operate a fleet of new generation sailing cargo vessels, powered 100% by wind when at sea.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Protagonist Therapeutics initiated with an Outperform at Leerink
- Alkermes price target lowered to $43 from $45 at Needham
- Harmony Biosciences price target lowered to $48 from $49 at Needham
- Alkermes price target raised to $35 from $34 at JPMorgan
- Promising Phase 3 Results for Takeda’s Oveporexton Boost Buy Rating